Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline Buys Back 1.3 Million Shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 06:28pm CET

GlaxoSmithKline PLC (>> GlaxoSmithKline plc) said Friday it has purchased 1,300,000 ordinary shares to be held in treasury.

MAIN FACTS:

-Highest price paid: 1455 pence per share.

-Lowest price paid: 1425 pence per share.

-Shares at 1610 GMT down 1%, at 1427 pence, valuing the company at GBP72 billion.

-By Mark Shapland, Dow Jones Newswires; +44 207 8429358; mark.shapland@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc, GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
01/20 GLAXOSMITHKLINE : *jefferies raises glaxosmithkline price target to 1780 pence -..
01/19 ASTRAZENECA : Luke Miels appointed President, Global Pharmaceuticals, GSK | GSK
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
01/19 GLAXOSMITHKLINE : *deutsche bank raises glaxosmithkline price target to 1800 pen..
01/19 TOP NEWS : GlaxoSmithKline Poaches AstraZeneca's Miels To Lead Pharma
01/19 GLAXOSMITHKLINE : Luke Miels appointed President, Global Pharmaceuticals, GSK
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave
01/19 GLAXOSMITHKLINE : Corporate executive team changes
01/19 GLAXOSMITHKLINE : Abbas Hussain to leave GSK
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 Why Gilead Is Undervalued
01/20 Pharma bigwigs acknowledge challenges with perceptions of pricing as Trump pr..
01/19 My 4th Quarter And Final 2016 Portfolio Review
01/19 WALL STREET BREAKFAST : First ECB Meeting Of The Year
01/19 Glaxo replaces exiting pharma head
Advertisement
Financials ( GBP)
Sales 2016 27 570 M
EBIT 2016 7 230 M
Net income 2016 2 316 M
Debt 2016 13 803 M
Yield 2016 5,24%
P/E ratio 2016 32,62
P/E ratio 2017 18,89
EV / Sales 2016 3,25x
EV / Sales 2017 3,02x
Capitalization 75 935 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,7  GBP
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-0.99%93 916
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.0.39%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results